



英文版仅为中文版之翻译，若中英歧义，请以中文版为准。

The English translation is for reference purposes only.

In the event of any discrepancy between the Chinese original and the English translation,  
the Chinese original shall prevail.

# 2025 第三季度报告

*The Third Quarter Report in 2025*



甘李药业股份有限公司  
GAN & LEE PHARMACEUTICALS.  
股票代码：603087.SH  
STOCK CODE: 603087.SH

## 目 录

## Contents

重要内容提示 Important Notes	3
一、主要财务数据 I Major Financial Data	4
二、股东信息 II Shareholder Information	11
三、季度财务报表 III Quarterly Financial Statements	15

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。

The Board of Directors and all Company directors warrant that there are no false records, misleading statements, or material omissions in this announcement. They are legally responsible for the truthfulness, accuracy, and completeness of its contents.

## 重要内容提示：

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。

公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务信息的真实、准确、完整。

第三季度财务报表是否经审计  
否

## Important Notes:

The Board of Directors, the Supervisory Committee and directors, supervisors, and senior management of the Company guarantee the truthfulness, accuracy and completeness of the contents of the quarterly report, and that there are no false records, misleading statements or material omissions, for which they shall be individually and jointly liable.

The legal representative, chief accountant, and head of accounting department (accounting supervisor) hereby certify that the financial report set out in the quarterly report is true, accurate and complete.

Whether the third quarter financial statements are audited  
No

# 主要财务数据

*Major Financial Data*



## 一、主要财务数据

## I Major Financial Data

## (一) 主要会计数据和财务指标

## (I) Major accounting data and financial indicators

单位：元 币种：人民币  
Unit: RMB

项目 Item	本报告期 Current reporting period	本报告期比上年同期增 减变动幅度(%) Change in the current reporting period over the same period of the previous year (%)	年初至报告期末 Beginning of the year to the end of the reporting period	年初至报告期末比上年同期 增减变动幅度(%) Change from the beginning of the year to the end of the reporting period over the same period of the previous year (%)
营业收入 Operating income	980,243,436.47	5.39	3,047,039,079.24	35.73
利润总额 Total profit	234,689,020.11	5.36	925,710,035.08	64.25
归属于上市公司股东的净利润 Net profit attributable to shareholders of the listed company	214,659,044.82	3.02	818,339,617.30	61.32
归属于上市公司股东的扣除非经常性损益的净利润 Net profit attributable to shareholders of the listed company after the deduction of non-recurring gains and losses	204,514,133.52	11.25	692,435,647.69	122.83
经营活动产生的现金流量净额 Net cash flows from operating activities	不适用 N/A	不适用 N/A	481,960,456.57	3.57
基本每股收益(元/股) Basic earnings per share (RMB per share)	0.36	2.86	1.38	62.35
稀释每股收益(元/股) Diluted earnings per share (RMB per share)	0.36	2.86	1.38	62.35
加权平均净资产收益率(%) Weighted average return on net assets (%)	1.92	增加0.05个百分点 Increase by 0.05 percentage points	7.21	增加2.60个百分点 Increase by 2.60 percentage points
		本报告期末 End of the current reporting period	上年度末 End of the previous year	本报告期末比上年度末增 减变动幅度(%) Change in the current reporting period over the end of the previous year (%)
总资产 Total Assets		12,142,757,686.96	12,042,916,391.88	0.83
归属于上市公司股东的所有者权益 Owners' equity attributable to shareholders of listed company		11,282,392,471.03	11,054,470,662.18	2.06

注：“本报告期”指本季度初至本季度末3个月期间，下同。

Note: "Current reporting period" refers to the three-month period from beginning to end of the current quarter, and the same applies hereinafter.

## (二) 非经常性损益项目和金额

## (II) Items and amounts of non-recurring gains and losses

单位：元 币种：人民币  
Unit: RMB

非经常性损益项目	Items of non-recurring gains and losses	本期金额 Amount for the current reporting period	年初至报告期末金额 Amount from the beginning of the year to the end of the reporting period	说明 Note
非流动性资产处置损益，包括已计提资产减值准备的冲销部分	Gains and losses on disposal of non-current assets, including the reversal of previously recognized asset impairment provisions		-107,351.01	
计入当期损益的政府补助，但与公司正常经营业务密切相关、符合国家政策规定、按照确定的标准享有、对公司损益产生持续影响的政府补助除外	Government grants recognized in profit or loss for the current period, excluding those closely related to the Company's business, in compliance with national policy regulations, received according to established criteria, and having a continuous impact on the Company's profit or loss	3,701,581.04	7,804,630.47	
除同公司正常经营业务相关的有效套期保值业务外，非金融企业持有金融资产和金融负债产生的公允价值变动损益以及处置金融资产和金融负债产生的损益	Gains and losses from changes in the fair value of financial assets and liabilities held by non-financial corporations, and gains and losses from the disposal of financial assets and liabilities, except for effective hedging operations related to the Company's normal business operations	10,971,872.43	83,421,054.65	
除上述各项之外的其他营业外收入和支出	Non-operating income and expenses other than those listed above	-2,304,772.68	56,963,308.23	
其他符合非经常性损益定义的损益项目	Other items of profit or loss that meet the definition of non-recurring gains and losses		628,068.62	
减：所得税影响额	Less: Amount affected by income tax	2,223,769.49	22,805,741.35	
合计	Total	10,144,911.30	125,903,969.61	

对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为的非经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。

For items of non-recurring gains and losses that the Company has recognized as items of non-recurring gains and losses not listed in "Interpretative Announcement for Information Disclosure of Companies Issuing Securities No. 1 - Non-recurring Gains and Losses" and the amount of which is material, as well as items defined as non-recurring gains and losses in "Interpretative Announcement for Information Disclosure of Companies Issuing Securities No. 1 - Non-recurring Gains and Losses", the reasons shall be explained.

单位：元 币种：人民币  
Unit: RMB

项目 Item	涉及金额 Amount	原因 Reason
递延收益摊销 Amortization of deferred income	6,944,688.50	本公司将资产相关的政府补助递延收益的摊销认定为经常性损益 The Company recognizes the amortization of deferred income from asset-related government grants as recurring gains and losses

### (三) 主要会计数据、财务指标发生变动的情况、原因 (III) Changes in major accounting data and financial indicators, and the reasons therefor

项目名称 Item	变动比例(%) Percentage of change (%)	主要原因 Main reason
营业收入_年初至报告期末 Operating income_from the beginning of the year to the end of the reporting period	35.73	见表格下方说明。 See note below the table.
利润总额_年初至报告期末 Total profit_from the beginning of the year to the end of the reporting period	64.25	主要系年初至报告期末营业收入较上年同期大幅增长所致。 Mainly due a significant increase in operating revenue from the beginning of the year to the end of the reporting period compared to the same period last year.
归属于上市公司股东的净利润_年初至报告期末 Net profit attributable to shareholders of listed companies_from the beginning of the year to the end of the reporting period	61.32	主要系年初至报告期末营业收入较上年同期大幅增长所致。 Mainly due a significant increase in operating revenue from the beginning of the year to the end of the reporting period compared to the same period last year.
归属于上市公司股东的扣除非经常性损益的净利润_年初至报告期末 Net profit attributable to shareholders of listed companies after deduction of non-recurring profits or losses_from the beginning of the year to the end of the reporting period	122.83	主要系年初至报告期末营业收入较上年同期大幅增长所致。 Mainly due a significant increase in operating revenue from the beginning of the year to the end of the reporting period compared to the same period last year.

项目名称	Item	变动比例 (%) Percentage of change (%)	主要原因	Main reason
基本每股收益_年初至 报告期末	Basic earnings per share_ from the beginning of the year to the end of the reporting period	62.35	主要系年初至报告期末 归属于上市公司股东的 净利润增加所致。	Mainly due to the increase in net profit attributable to shareholders of the listed company from the beginning of the year to the end of the reporting period.
稀释每股收益_年初至 报告期末	Diluted earnings per share_ from the beginning of the year to the end of the reporting period	62.35	主要系年初至报告期末 归属于上市公司股东的 净利润增加所致。	Mainly due to the increase in net profit attributable to shareholders of the listed company from the beginning of the year to the end of the reporting period.

说明：  
营业收入\_年初至报告期末变动原  
因：

2025年前三季度，营业收入为30.47  
亿元，与上年同期增加8.02亿元，同  
比增长35.73%，具体情况如下：

Note:  
The reasons for the changes in operating income\_from the  
beginning of the year to the end of the reporting period are as  
follows:

In the first three quarters of 2025, operating revenue reached  
RMB 3.047 billion, an increase of RMB 802 million compared to  
the same period last year, representing a year-on-year growth of  
35.73%, with the details as follows:

#### 营业收入分地区情况 Operating income by region

单位：亿元

Unit: RMB 100 million

分地区 Region	2025年前三季度 Operating income for the first three quarters of 2025		
	金额 Amount	同期变动额 Change amount for the same period	同期变动率 Change rate for the same period
国内-销售收入 Domestic - Sales revenue	26.90	8.22	44.01%
国际-销售收入 International - Sales revenue	3.53	1.10	45.52%
国际-特许经营权服务收入 International - Revenue from franchise services	0.04	-1.30	-96.82%
营业收入合计 Total operating income	30.47	8.02	35.73%

注：表中数据尾差是由于四舍五入所  
致


Note: The discrepancies in the table data are due to rounding.

(1) 2025年前三季度，国内胰岛素制剂产品销量较上年同期均实现增长。胰岛素接续集采后，公司胰岛素制剂产品价格增长(胰岛素接续集采于2024年5月开始在(省)区陆续执行)，国内胰岛素制剂产品销量与价格增长效应协同显现充分释放，为收入增长提供了有力支撑。2025年前三季度，国内胰岛素制剂产品销售收入为26.24亿元，较上年同期增加8.22亿元，销量增长对收入增长的影响和价格增长对收入增长的影响分别为4.92亿元、3.30亿元，详见图1。

(1) In the first three quarters of 2025, domestic insulin preparation product sales increased year-on-year. Following the implementation of the successive insulin-specific centralized procurement (which commenced in May 2024 across various provinces and regions), the Company's insulin preparation experienced price increases. The synergistic effect of both volume growth and price increases in insulin preparation sales was fully realized, providing strong support for revenue growth. In the first three quarters of 2025, domestic insulin preparation product sales revenue reached RMB 2.624 billion, an increase of RMB 822 million compared to the same period last year. The contributions to revenue growth from volume growth and price growth were RMB 492 million and RMB 330 million, respectively, as detailed in Figure 1.

图1: 国内制剂收入变动因素分析(单位: 亿元)

Figure 1: Analysis of factors influencing domestic preparation revenue changes (Unit: RMB 100 million)



注释: 销量影响 = (2025年1-9月销售量 - 2024年1-9月销售量) \* 2024年1-9月平均单价; 价格影响 = (2025年1-9月平均价格 - 2024年1-9月平均价格) \* 2025年1-9月销售量。

Note: Sales volume impact = (Sales volume of Jan.to Sept.in 2025 - Sales volume of Jan.to Sept.in 2024) \* Average unit price of Jan. to Sept. in 2024  
 Price impact = (Average unit price of Jan.to Sept. in 2025 - Average unit price of Jan.to Sept. in 2024) \* Sales volume of Jan.to Sept.in 2025

(2) 2025年前三季度，公司实现国际销售收入为3.53亿元，较上年同期增加1.10亿元，同比增长45.52%。该增长主要得益于公司持续推进全球化战略，通过持续优化产品质量与提升客户服务水平，在巴西等关键市场赢得客户更多的信赖，带动订单提升，进一步巩固并扩大了在国际市场的份额。

在长期合作方面，公司与巴西相关方就生产开发伙伴关系计划项目(PDP项目)正式签署为期10年的《技术转移与供应协议》及《供应框架协议》。根据《供应框架协议》，10年累计订单金额不低于人民币30亿元(含税，最终以实际订单金额为准)。本次合作中，各方优势互补、协同并进，形成“技术输出—本土化落地—长期采购”的闭环，标志着双方在战略合作基础上迈入全新阶段。

(3) 在特许权服务收入方面，2025年前三季度较上年同期减少1.30亿元，主要原因为去年公司在欧美市场的合作开发取得新进展，并依据相关协议确认了里程碑节点收入，该部分收入属于阶段性确认，本期无同类事项发生。

(2) In the first three quarters of 2025, the company achieved international sales revenue of RMB 353 million, an increase of RMB 110 million compared to the same period last year, representing a year-on-year growth of 45.52%. This growth was primarily driven by the Company's continued advancement of its globalization strategy. Through ongoing optimization of product quality and enhancement of customer service levels, the company gained greater trust from customers in key markets such as Brazil, leading to increased orders and further consolidating and expanding its market share internationally.

Regarding long-term cooperation, the Company has formally signed a 10-year "Technology Transfer and Supply Agreement" and "Supply Framework Agreement" with Brazilian counterparts for the Production Development Partnership (Parcerias para o Desenvolvimento Produtivo, PDP) project. Under the Supply Framework Agreement, the cumulative order value over 10 years shall not be less than RMB 3 billion (including tax, subject to final actual order amounts). This collaboration leverages complementary strengths and synergistic progress among all parties, establishing a closed-loop model of "technology export—localization implementation—long-term procurement." It marks a new phase in the strategic partnership between the two sides.

(3) Regarding franchise service revenue, the first three quarters of 2025 saw a decrease of RMB 130 million compared to the same period last year. This was primarily due to the Company achieving new progress in collaborative development projects in the EU and the US markets last year, which resulted in the recognition of milestone payments under relevant agreements. Such revenue is recognized on a phased basis, and no comparable events occurred during the current period.

# 股东信息

*Shareholder Information*



## 二、股东信息

## II Shareholder Information

## (一) 普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表

## (I) Total number of ordinary shareholders, the number of preferred shareholders with voting rights restored, and the top ten shareholders' shareholding

单位：股  
Unit: Share

报告期末普通股股东总数 Total number of ordinary shareholders at the end of the current reporting period	94,714	报告期末表决权恢复的优先股股东总数(如有) Total number of preferred shareholders with voting rights restored at the end of the current reporting period (if any)	0
---	--------	---	---

前10名股东持股情况(不含通过转融通出借股份)  
Shareholdings of top ten shareholders (excluding shares lending through securities lending)

股东名称 Shareholder name	股东性质 Nature of shareholders	持股数量 Number of shares held	持股比例(%) Shareholding ratio (%)	持有有限售条件 股份数量 Number of restricted shares held	质押、标记或冻结情况 Status of shares pledged, tagged, or frozen	股份状态 Share status	数量 Number
甘忠如 Zhongru Gan	境内自然人 Domestic natural person	205,643,757	34.42	28,508,550	无 None		
北京旭特宏达科技有限公司 Beijing Xute Hongda Technology Co., Ltd.	境内非国有法人 Domestic non-state-owned legal entity	32,073,734	5.37		质押 Pledged		24,010,000
香港中央结算有限公司 Hong Kong Securities Clearing Company Limited	其他 Other	8,004,169	1.34		无 None		
甘喜茹 Xiru Gan	境内自然人 Domestic natural person	6,006,676	1.01		质押 Pledged		970,000
中国农业银行股份有限公司— 中证500交易型开放式指数证券投资 基金 Agricultural Bank of China Limited - CSI 500 Exchange Traded Open-End Index Securities Investment Fund	其他 Other	5,259,555	0.88		无 None		
中国银行股份有限公司—招商 国证生物医药指数分级证券投资 基金 Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund	其他 Other	4,904,300	0.82		无 None		
HH G&L Holdings (HK) Limited	境外法人 Overseas legal entity	4,296,032	0.72	4,296,032	无 None		
上海银行股份有限公司—银华 中证创新药产业交易型开放式 指数证券投资基金 Shanghai Bank Co., Ltd. - Yinhua CSI Innovative Pharmaceutical Industry Exchange-Traded Fund	其他 Other	3,577,294	0.60		无 None		

单位：股  
Unit: Share

前10名股东持股情况(不含通过转融通出借股份)						
Shareholdings of top ten shareholders (excluding shares lending through securities lending)						
股东名称 Shareholder name	股东性质 Nature of shareholders	持股数量 Number of shares held	持股比例(%) Shareholding ratio (%)	持有有限售条件 股份数量 Number of restricted shares held	质押、标记或冻结情况 Status of shares pledged, tagged, or frozen	
					股份状态 Share status	数量 Number
招商银行股份有限公司－南方阿尔法混合型证券投资基金 China Merchants Bank Co., Ltd. - Southern Alpha Hybrid Securities Investment Fund	其他 Other	2,646,874	0.44		无 None	
甘一如 Yiru Gan	境内自然人 Domestic natural person	2,215,637	0.37		无 None	

单位：股  
Unit: Share

前10名无限售条件股东持股情况(不含通过转融通出借股份)			
Shareholdings of the top ten shareholders with unlimited trading conditions(excluding shares lending through securities lending)			
股东名称 Shareholder name	持有无限售条件流通股的 数量 Number of unlimited shares outstanding	股份种类及数量 Category and number of shares	
		股份种类 Category	数量 Number
甘忠如 Zhongru Gan	177,135,207	人民币普通股 RMB ordinary shares	177,135,207
北京旭特宏达科技有限公司 Beijing Xute Hongda Technology Co.,Ltd	32,073,734	人民币普通股 RMB ordinary shares	32,073,734
香港中央结算有限公司 Hong Kong Securities Clearing Company Limited	8,004,169	人民币普通股 RMB ordinary shares	8,004,169
甘喜茹 Xiru Gan	6,006,676	人民币普通股 RMB ordinary shares	6,006,676
中国农业银行股份有限公司－中证500交易型开放式指数证券投资基金 Agricultural Bank of China Limited - CSI 500 Exchange Traded Open-End Index Securities Investment Fund	5,259,555	人民币普通股 RMB ordinary shares	5,259,555
中国银行股份有限公司－招商国证生物医药指数分级证券投资基金 Bank of China Limited - China Merchants CSI Biomedical Index Split-level Securities Investment Fund	4,904,300	人民币普通股 RMB ordinary shares	4,904,300

前10名无限售条件股东持股情况(不含通过转融通出借股份)			
Shareholdings of the top ten shareholders with unlimited trading conditions(excluding shares lending through securities lending)			
股东名称 Shareholder name	持有无限售条件流通股的 数量 Number of unlimited shares outstanding	股份种类及数量 Category and number of shares	
		股份种类 Category	数量 Number
上海银行股份有限公司—银华中证创新药产业交易型开放式指数证券投资基金 Shanghai Bank Co., Ltd. - Yinhua CSI Innovative Pharmaceutical Industry Exchange-Traded Fund	3,577,294	人民币普通股 RMB ordinary shares	3,577,294
招商银行股份有限公司—南方阿尔法混合型证券投资基金 China Merchants Bank Co., Ltd. - Southern Alpha Hybrid Securities Investment Fund	2,646,874	人民币普通股 RMB ordinary shares	2,646,874
甘一如 Yiru Gan	2,215,637	人民币普通股 RMB ordinary shares	2,215,637
中国人寿保险股份有限公司—传统—普通保险产品—005L—CT001沪 China Life Insurance Company Limited - Traditional - Ordinary Insurance Product - 005L - CT001 Shanghai	2,107,300	人民币普通股 RMB ordinary shares	2,107,300
上述股东关联关系或一致行动的说明 Explanation of the above shareholders' affiliation or concerted action	截至报告披露日,公司控股股东、实际控制人甘忠如持有北京旭特宏达科技有限公司96.28%的股权;甘喜茹为甘忠如胞妹。除以上情况外,其他股东之间不存在关联关系或一致行动。 Zhongru Gan, the controlling shareholder and actual controller of the Company, holds 96.28% of the shares of Beijing Xute Hongda Technology Co.,Ltd. Xiru Gan is the sibling of Zhongru Gan. Apart from the above, there is no affiliation or concerted action among other shareholders.		
前10名股东及前10名无限售股东参与融资融券及转融通业务情况说明(如有) Explanation on the participation of the top ten shareholders and the top ten unlimited shareholders in the margin financing and lending of shares in the transfer and refinancing business (if any)	不适用 N/A		

# 季度财务报表

*Quarterly Financial Statements*



## 三、季度财务报表

## III Quarterly Financial Statements

## (一) 财务报表

## (I) Financial statements

## 合并资产负债表

## Consolidated statement of financial position

2025年9月30日  
September 30, 2025编制单位:甘李药业股份有限公司  
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计  
Unit: RMB Audit type: Unaudited

项目	Item	2025年9月30日 September 30, 2025	2024年12月31日 December 31, 2024
<b>流动资产:</b>	<b>Current Assets:</b>		
货币资金	Cash and Cash equivalents	2,064,233,725.12	902,777,760.68
交易性金融资产	Financial assets held for trading	1,102,024,616.43	1,500,496,835.63
应收票据	Notes receivable	5,241,627.70	12,246,237.38
应收账款	Accounts receivable	529,627,542.60	213,714,496.82
应收款项融资	Financing receivables	19,767,346.00	20,758,005.45
预付款项	Prepayments	78,497,686.89	56,562,468.46
其他应收款	Other receivables	4,004,977.13	1,847,488.41
存货	Inventories	1,125,094,142.08	1,052,906,832.75
一年内到期的非流动资产	Non-current assets due within one year	7,162,141.25	5,089,557.41
其他流动资产	Other current assets	32,843,010.07	24,458,526.06
流动资产合计	Total current assets	4,968,496,815.27	3,790,858,209.05
<b>非流动资产:</b>	<b>Non-current Assets:</b>		
债权投资	Debt investments	508,147,397.07	497,027,269.78
长期应收款	Long-term receivables	6,318,665.85	7,669,407.96
其他非流动金融资产	Other non-current financial assets	72,190,190.44	11,713,152.96
固定资产	Fixed assets	2,472,416,874.48	2,615,687,526.41
在建工程	Construction in progress	1,348,296,006.45	1,262,027,468.83
使用权资产	Right-of-use assets	3,264,225.79	4,323,594.06
无形资产	Intangible assets	263,726,341.50	273,059,639.42
开发支出	Development expenditures	1,392,805,454.24	917,812,401.72
长期待摊费用	Long-term deferred expenses	5,774,139.35	7,101,160.03
递延所得税资产	Deferred tax assets	228,780,920.03	206,935,277.52
其他非流动资产	Other non-current assets	872,540,656.49	2,448,701,284.14
非流动资产合计	Total non-current assets	7,174,260,871.69	8,252,058,182.83
资产总计	Total assets	12,142,757,686.96	12,042,916,391.88

**合并资产负债表 (续)**  
Consolidated statement of financial position (Continued)

项目	Item	2025年9月30日 September 30, 2025	2024年12月31日 December 31, 2024
<b>流动负债：</b>	<b>Current Liabilities</b>		
应付账款	Accounts payable	126,494,605.62	129,129,386.84
预收款项	Advance received from customers	30,275.24	
合同负债	Contract liabilities	49,109,519.63	63,254,168.23
应付职工薪酬	Payroll and employee benefits payable	168,727,631.84	150,681,683.52
应交税费	Taxes payable	15,859,468.75	11,191,413.07
其他应付款	Other payables	320,749,555.25	426,587,948.23
一年内到期的非流动负债	Non-current liabilities due within one year	5,793,669.61	10,056,983.05
其他流动负债	Other current liabilities	3,692,205.90	10,230,151.30
流动负债合计	Total current liabilities	690,456,931.84	801,131,734.24
<b>非流动负债：</b>	<b>Non-current Liabilities:</b>		
租赁负债	Lease liabilities	2,582,321.88	3,306,003.23
长期应付款	Long-term payables	2,646,761.09	2,973,351.09
递延收益	Deferred income	164,679,201.12	168,923,889.62
递延所得税负债	Deferred tax liabilities		12,110,751.52
非流动负债合计	Total non-current liabilities	169,908,284.09	187,313,995.46
负债合计	Total liabilities	860,365,215.93	988,445,729.70
<b>所有者权益(或股东权益)：</b>	<b>Owners' (or Shareholders') equity:</b>		
实收资本(或股本)	Paid-in capital (or share capital)	597,304,969.00	601,065,290.00
资本公积	Capital reserve	3,521,754,334.76	3,590,961,537.76
减：库存股	Less: Treasury shares	120,692,360.00	200,846,739.31
其他综合收益	Other comprehensive income	3,630,190.90	4,036,955.66
盈余公积	Surplus reserve	300,532,645.00	300,532,645.00
未分配利润	Retained earnings	6,979,862,691.37	6,758,720,973.07
归属于母公司所有者权益(或股东权益)合计	Total owner's equity (or shareholders' equity) attributable to the parent company	11,282,392,471.03	11,054,470,662.18
所有者权益(或股东权益)合计	Total owners' (or shareholders') equity	11,282,392,471.03	11,054,470,662.18
<b>负债和所有者权益(或股东权益)总计</b>	<b>Total liabilities and owners' (or Shareholders') equity</b>	<b>12,142,757,686.96</b>	<b>12,042,916,391.88</b>

公司负责人： 陈伟

主管会计工作负责人： 孙程

会计机构负责人： 周丽

Legal Representative: Wei Chen

Chief Accountant: Cheng Sun

Head of Accounting Department:

Li Zhou

## 合并利润表

### Consolidated Income Statement

2025年1—9月  
Jan. to Sept., 2025编制单位:甘李药业股份有限公司  
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计  
Unit: RMB Audit type: Unaudited

项目	Item	2025年前三季度 First three quarters of 2025(Jan.to Sept.)	2024年前三季度 First three quarters of 2024(Jan. to Sept.)
一、营业总收入	I. Total operating Revenue	3,047,039,079.24	2,245,006,087.12
其中:营业收入	Of which: Operating income	3,047,039,079.24	2,245,006,087.12
二、营业总成本	II. Total operating costs	2,275,937,092.07	1,921,772,067.24
其中:营业成本	Of which: Operating costs	725,750,228.68	553,241,458.86
税金及附加	Taxes and surcharges	28,744,855.36	22,246,574.82
销售费用	Selling expenses	978,990,601.81	831,334,688.22
管理费用	General and administrative expenses	196,121,275.25	169,962,996.50
研发费用	R&D expenses	407,861,819.05	403,442,931.89
财务费用	Financial expenses	- 61,531,688.08	-58,456,583.05
加:其他收益	Add: Other income	15,707,102.52	14,065,608.78
投资收益(损失以“—”号填列)	Investment income or loss (loss is indicated with "-")	10,823,936.85	55,851,319.43
公允价值变动收益(损失以“—”号填列)	Gain or loss on the changes in fair value (loss is indicated with "-")	72,066,564.13	167,902,884.11
信用减值损失(损失以“—”号填列)	Credit impairment losses (loss is indicated with "-")	-1,923,291.76	529,401.96
资产减值损失(损失以“—”号填列)	Assets impairment losses (loss is indicated with "-")	876,940.21	16,817.47
资产处置收益(损失以“—”号填列)	Gain or loss from disposal of assets (loss is indicated with "-")		658,001.36
三、营业利润(亏损以“—”号填列)	III. Operating Profit (loss is indicated with "-")	868,653,239.12	562,258,052.99
加:营业外收入	Add: Non-operating income	62,344,001.18	2,164,705.30
减:营业外支出	Less: Non-operating expenses	5,287,205.22	818,059.37
四、利润总额(亏损总额以“—”号填列)	IV. Profit before tax (loss is indicated with "-")	925,710,035.08	563,604,698.92
减:所得税费用	Less: Income tax expense	107,370,417.78	56,339,499.40
五、净利润(净亏损以“—”号填列)	V. Net Profit (net loss is indicated with "-")	818,339,617.30	507,265,199.52
(一)按经营持续性分类	(I) Categorized by operation continuity		
1.持续经营净利润(净亏损以“—”号填列)	1. Net profit from continuing operations (loss is indicated with "-")	818,339,617.30	507,265,199.52

**合并利润表 (续)**  
**Consolidated Income Statement (Continued)**

项目	Item	2025年前三季度 First three quarters of 2025(Jan.to Sept.)	2024年前三季度 First three quarters of 2024(Jan. to Sept.)
(二) 按所有权归属分类	(II) Categorized by ownership		
1. 归属于母公司股东的净利润(净亏损以“-”号填列)	1. Net profit attributable to owners of the parent company (net loss is indicated with "-")	818,339,617.30	507,265,245.69
2. 少数股东损益(净亏损以“-”号填列)	2. Net profit attributable to non-controlling interests (net loss is indicated with "-")		-46.17
<b>六、其他综合收益的税后净额</b>	<b>VI. Other comprehensive income net of tax</b>	-406,764.76	-865,256.02
(一) 归属母公司所有者的其他综合收益的税后净额	(I) Other comprehensive income, net of tax, attributable to owners of the parent company	-406,764.76	-865,256.02
1. 不能重分类进损益的其他综合收益	1. Other comprehensive income cannot be reclassified to profit or loss		
2. 将重分类进损益的其他综合收益	2. Other comprehensive income to be reclassified to profit or loss	-406,764.76	-865,256.02
(1) 外币财务报表折算差额	(1) Exchange differences on translation of foreign currency financial statements	-406,764.76	-865,256.02
(二) 归属于少数股东的其他综合收益的税后净额	(II) Other comprehensive income net of tax attributable to non-controlling interests		
<b>七、综合收益总额</b>	<b>VII. Total Comprehensive Income</b>	817,932,852.54	506,399,943.50
(一) 归属于母公司所有者的综合收益总额	(I) Total comprehensive income attributable to owners of the parent company	817,932,852.54	506,399,989.67
(二) 归属于少数股东的综合收益总额	(II) Total comprehensive income attributable to non-controlling interests		-46.17
<b>八、每股收益：</b>	<b>VIII. Earnings Per Share:</b>		
(一) 基本每股收益(元/股)	(I) Basic earnings per share (RMB per share)	1.38	0.85
(二) 稀释每股收益(元/股)	(II) Diluted earnings per share (RMB per share)	1.38	0.85

本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0元，上期被合并方实现的净利润为：0元。

As for a business combination under the same control in the current period, the net profit generated by the merged party before the combination was RMB 0, and that generated during the previous period was RMB 0.

公司负责人：陈伟

主管会计工作负责人：孙程

会计机构负责人：周丽

Legal Representative: Wei Chen

Chief Accountant: Cheng Sun

Head of Accounting Department: Li Zhou

## 合并现金流量表

### Consolidated Statement of Cash Flows

2025年1—9月  
Jan.to Sept.,2025编制单位:甘李药业股份有限公司  
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计  
Unit: RMB Audit type:Unaudited

项目	Item	2025年前三季度 First three quarters of 2025(Jan.to Sept.)	2024年前三季度 First three quarters of 2024(Jan. to Sept.)
<b>一、经营活动产生的现金流量:</b>			
<b>I. Cash Flows from Operating Activities:</b>			
销售商品、提供劳务收到的现金	Cash receipts from the sale of goods and the rendering of services	2,799,253,112.31	2,405,077,571.10
收到的税费返还	Tax refunds received	85,506,119.06	67,547,714.01
收到其他与经营活动有关的现金	Cash received relating to other operating activities	75,818,636.58	9,914,697.24
经营活动现金流入小计	Sub-total of cash inflows from operating activities	2,960,577,867.95	2,482,539,982.35
购买商品、接受劳务支付的现金	Cash paid for purchase of goods and services	725,969,731.03	641,934,128.62
支付给职工及为职工支付的现金	Cash paid to and on behalf of employees	764,768,091.94	639,530,019.39
支付的各项税费	Cash paid for taxes	237,385,212.17	81,065,798.62
支付其他与经营活动有关的现金	Cash paid relating to other operating activities	750,494,376.24	654,669,741.87
经营活动现金流出小计	Sub-total of cash outflows from operating activities	2,478,617,411.38	2,017,199,688.50
经营活动产生的现金流量净额	Net cash flows from operating activities	481,960,456.57	465,340,293.85
<b>二、投资活动产生的现金流量:</b>			
<b>II. Cash Flows from Investing Activities:</b>			
收回投资收到的现金	Cash received from disposal of investment	4,862,623,970.00	7,070,151,578.75
取得投资收益收到的现金	Cash receipts from investment income	79,501,731.75	21,503,965.64
处置固定资产、无形资产和其他长期资产收回的现金净额	Net proceeds from disposal of fixed assets, intangible assets, and other long-term assets	18,056.00	
收到其他与投资活动有关的现金	Other cash received related to investing activities		2,484,645.75
投资活动现金流入小计	Sub-total of cash inflows from investing activities	4,942,143,757.75	7,094,140,190.14
购建固定资产、无形资产和其他长期资产支付的现金	Purchase of fixed assets, intangible assets, and other non-current assets	627,863,920.32	294,762,231.72
投资支付的现金	Cash paid for investments	3,982,756,561.06	7,279,256,512.68

**合并现金流量表 (续)**  
Consolidated Statement of Cash Flows (Continued)

项目	Item	2025年前三季度 First three quarters of 2025(Jan.to Sept.)	2024年前三季度 First three quarters of 2024(Jan. to Sept.)
支付其他与投资活动有关的现金	Cash paid relating to other investing activities		
投资活动现金流出小计	Sub-total of cash outflows from investing activities	4,610,620,481.38	7,574,018,744.40
投资活动产生的现金流量净额	Net cash flows from investing activities	331,523,276.37	-479,878,554.26
<b>三、筹资活动产生的现金流量：</b>	<b>III. Cash Flows from Financing Activities:</b>		
吸收投资收到的现金	Cash received from investment absorption		139,321,600.00
筹资活动现金流入小计	Subtotal of cash inflows from financing activities		139,321,600.00
分配股利、利润或偿付利息支付的现金	Cash paid for dividend and profit distribution or interest payment	597,197,899.00	118,247,550.00
支付其他与筹资活动有关的现金	Cash payments relating to other financing activities	140,071,249.60	19,159,981.31
筹资活动现金流出小计	Sub-total of cash outflows from financing activities	737,269,148.60	137,407,531.31
筹资活动产生的现金流量净额	Net cash flow from financing activities	-737,269,148.60	1,914,068.69
四、汇率变动对现金及现金等价物的影响	IV. Effect of exchange rate changes on cash and cash equivalents	2,686,658.89	-1,572,201.80
五、现金及现金等价物净增加额	V. Net increase in cash and cash equivalents	78,901,243.23	-14,196,393.52
加：期初现金及现金等价物余额	Add: Opening balance of cash and cash equivalents	260,055,136.76	286,438,980.59
六、期末现金及现金等价物余额	VI. Closing balance of cash and cash equivalents	338,956,379.99	272,242,587.07

公司负责人： 陈伟

主管会计工作负责人： 孙程

会计机构负责人： 周丽

Legal Representative: Wei Chen

Chief Accountant: Cheng Sun

Head of Accounting Department:

Li Zhou

特此公告

Hereby announced officially.

甘李药业股份有限公司董事会  
The Board of Directors of Gan & Lee Pharmaceuticals.

2025年10月29日  
October 29, 2025



SCIENCE EXCELLENCE

甘李药业有限公司

Gan & Lee Pharmaceuticals.

地址：北京市通州区潮县镇南凤西一路8号

Address: No. 8, Nanfeng West 1st Street, Huoxian, Tongzhou District, Beijing

网址：<http://www.ganlee.com>

Website: <https://www.ganlee.com.cn>

电话：+86 010-80593699

Tel: +86 010-80593699

邮编：101109

Post code : 101109